A clinical trial has been carried out to assess the safety, tolerability, and clinical efficacy of omalizumab in treating mild to moderate systemic lupus erythematosus (SLE).
“A potential advantage of omalizumab in SLE is a side effect profile different from immunosuppressive drugs and a convenient once-a-month subcutaneous administration schedule," Hasni and colleagues wrote. "Overall, this is the first trial to test the safety and potential efficacy of blocking IgE autoantibodies as a novel non-immunosuppressive agent in treatment of SLE. Additional larger studies will be needed to more fully evaluate the efficacy and safety of omalizumab in SLE”
For the full study please click here.